Marker Therapeutics (MRKR)

• Market cap: $33.9M
• 1 day: 1.88%
• 5 days: -5.94%
• 1 month: 19.50%
• 3 months: 29.25%
• 6 months: -15.37%
• Year to date: -30.40%
• 1 year: -1.30%
• 5 years: -87.21%
• 10 years: -93.05%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Employees: 8

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0% more funds holding

Funds holding: 28 [Q2] → 28 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0.02% less ownership

Funds ownership: 22.56% [Q2] → 22.54% (-0.02%) [Q3]

48% less capital invested

Capital invested by funds: $10.9M [Q2] → $5.67M (-$5.26M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $19 400% upside
• Avg. target: $19 400% upside
• High target: $19 400% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Ladenburg Thalmann Aydin Huseynov 27% 1-year accuracy 3 / 11 met price target

400% upside $19

Buy Maintained

21 Oct 2024